Drug
Granisetron
Granisetron: highest development phase Approved, developed by Heron Therapeutics, Kyowa Kirin, Sandoz. 4 trial records tracked on RxWires.
- Highest phase
- Approved
- Developer
- Heron Therapeutics, Kyowa Kirin, Sandoz
Trials
| Drug | Phase | Indication |
|---|---|---|
| GRANISETRON HYDROCHLORIDE | Approved | |
| GRANISETRON EXTENDED RELEASE INJECTION (GERSC) NCT04085393 | Phase 2 | Chemotherapy-induced Nausea and Vomiting |
| Granisetron NCT04501211 | Phase 2 | Gastroparesis |
| Granisetron NCT01952886 | Phase 2 | Malignant Glioma |
Latest
No recent events.
Follow Granisetron on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.